ASDERA develops interventions for unmet needs by utilizing a patented computational biostatistics platform to identify complex genetic risk factors in small (n>500) epidemiological and phase 2/3 studies.

  The ASDERA time-/pipeline:

  1. Validation: Confirmation of known drug targets in epilepsy
    (2013, Pharmacogenomics)
  2. Proof-of-principle: L-fucose in Crohn's disease 
    (in progress, from 2006 dbGaP data)
  3. Outlicensed: A derivative of mefenamic acid against mutism in autism (2014, Nature: Transl. Psychiatry, $500M valuation)
  4. Current treatment lead: Derivatives of HP-a-cyclodextrin
    (pat. pending) against progression of
    - carcinomas (breast cancer,
    neurodegeneration (Alzheimer's, Parkinson's, Huntingtion's, ...) 
  5. Current nutraceutical lead: Derivatives of a-cyclodextrin
    (pat. pending) for
    - reducing serum phospholipids to help improving health in aging.